

National Treatment Purchase Fund Board

Financial Statements

For Year Ended 31 December 2016

National Treatment Purchase Fund Board

Table of Contents

	Page
Table of Contents	2
General Information	3
Statement of Board Members' Responsibilities	4
Statement of Internal Financial Control	5 - 6
Report of the Comptroller and Auditor General	7
Statement of Income and Expenditure and Retained Revenue Reserves	8
Statement of Financial Position	9
Statement of Cash Flows	10
Notes to the Financial Statements	11 - 22

National Treatment Purchase Fund Board

General Information

Board members :	John Horan (Chairman) Sheila Bailey (appointed 28/02/14) Bernadette Costello (appointed 28/02/14) Patrick Gibbons (appointed 28/02/14) Terry McWade (appointed 28/02/14) James Melly (appointed 28/02/14) Jack Nagle (appointed 28/02/14) Brendan O'Donoghue (appointed 28/02/14) Anne-Marie Taylor (appointed 28/02/14)
Board Secretary:	Liz Lottering
Head Office:	Ashford House Tara Street Dublin 2
Telephone No:	+353 1 6427 101
Fax No:	+353 1 6427 102
Website:	www.ntpf.ie
Auditors:	Comptroller and Auditor General 3 Mayor Street Upper North Wall Dublin 1
Main Bankers:	AIB Bank Limited Swords Road Santry Dublin 9
Solicitors:	Philip Lee Solicitors 7/8 Wilton Terrace Dublin 2

National Treatment Purchase Fund Board

Board Members' Report

For the year ended 31 December 2016

Statement of Board Members' Responsibilities

The Board is required by the National Treatment Purchase Fund Board (Establishment) Order 2004 to prepare financial statements for each financial year which give a true and fair view of the financial state of affairs of the NTPF Board and of its income and expenditure for the year reported.

In preparing these financial statements, the NTPF Board is required to:

- Select suitable accounting policies and apply them consistently
- Make judgements and estimates that are reasonable and prudent
- Disclose and explain any material departures from applicable accounting standards
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the Board will continue in operation.


The Board is responsible for keeping proper accounting records which disclose, with reasonable accuracy at any time, its financial position and enable it to ensure that the financial statements comply with accounting standards generally accepted in Ireland and comply with the National Treatment Purchase Fund Board (Establishment) Order 2004.

The Board is also responsible for safeguarding the assets of the organisation and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the NTPF Board:



John Horan
Chairperson
Date: 22/01/2018



Terry McWade
Board Member
Date: 22/01/2018

National Treatment Purchase Fund Board

Statement of Internal Financial Control

Responsibility for the System of Internal Financial Control

I as Chairman of the Board make this statement in accordance with the requirements set out in the Department of Public Expenditure and Reform's code of Practice for the Governance of State Bodies (2009). The Chairman and Members of the Board of the National Treatment Purchase Fund acknowledge their responsibility for ensuring that an effective system of internal financial control is maintained and operated.

Roles and Responsibilities in relation to the Waiting List Initiative

In May 2015, the Health Service Executive (HSE) tendered for private hospitals to provide inpatient and outpatient services to all patients on public hospital waiting lists for in excess of 18 months. Individual hospitals were selected to provide specified procedures/treatments at agreed rates. The HSE arranged for treatment to be delivered to patients on its waiting lists. NTPF provided some administrative support to this initiative by way of disbursing payments to the participating private hospitals during 2015 and 2016.

Purpose of the System of Internal Control

A system of internal financial control is designed to reduce rather than eliminate risk. Such a system can provide only reasonable and not absolute assurance that assets are safeguarded, transactions are authorised and properly recorded and that material errors or irregularities are either prevented or detected in a timely manner.

It is confirmed that the system of internal control was in place for the whole of the financial year under review, being the year ended 31 December 2016.

Key Control Procedures

The following steps have been taken to ensure an appropriate control environment:

- The Board has a regular schedule of meetings at which it is provided with updated reports of expenditure trends and other financial planning and budgetary control issues.
- An Audit and Risk Committee has been established and operates under formal terms of reference that support a strong financial control environment. The Committee reports to the Board regularly.
- An Internal Audit Function, which is outsourced to a professional accountancy firm, operates in accordance with a written charter. Its work is informed by an analysis of the business risks to which the National Treatment Purchase Fund is exposed and its annual internal plans are based on this analysis. The internal audit function reports to the Audit and Risk Committee. Any instances of fraud or other irregularities that are identified are addressed by management and, where required, the appropriate authorities are notified.
- For the year under review, the Audit and Risk Committee, on behalf of the Board, arranged for Internal Audit to conduct a review of internal financial controls at the National Treatment Purchase Fund.

National Treatment Purchase Fund Board

Statement of Internal Financial Control (cont.)

- Management responsibilities are clearly assigned, with corresponding accountability.
- Reporting procedures are well established at all levels where responsibility for financial management has been assigned.

The Risk and Control Framework

The system of internal financial control is continually developed, maintained and monitored in response to the emerging requirements of the organisation. There is a framework of administration procedures and regular management reporting in place including segregation of duties and a system of delegation and accountability.

The following is an outline of key processes and procedures designed to provide effective internal financial control, which are in place across the organisation:

- The Board has formulated a Strategy and Action Plan 2017-2019. The purpose of the document is to outline the National Treatment Purchase Fund's key strategic priorities for the years 2017-2019. This is accompanied by an Action Plan focused on key deliverables over the three year life-span of the strategy.
- There is an appropriate budgeting system with an annual budget which is kept under review by senior management.
- There are regular reviews by senior management of periodic and annual financial reports which indicate financial performance against forecast.
- A risk management system operates within the National Treatment Purchase Fund Board. Formal procedures have been established for reporting significant control failures and ensuring appropriate corrective action.
- There are systems in place aimed at ensuring the security of the ICT systems.
- The National Treatment Purchase Fund is compliant with all pay and travel circulars issued by the Department of Public Expenditure and Reform and all relevant guidelines regarding procurement.

Annual Review of Controls

I confirm that a review of the effectiveness of the system of internal financial controls was carried out in respect of 2016.



John Horan
Chairperson
Date: 22/01/2018



Comptroller and Auditor General

Report for presentation to the Houses of the Oireachtas

National Treatment Purchase Fund Board

I have audited the financial statements of the National Treatment Purchase Fund Board for the year ended 31 December 2016 under Section 5 of the Comptroller and Auditor General (Amendment) Act 1993. The financial statements comprise the statement of income and expenditure and retained revenue reserves, the statement of financial position, the statement of cash flows and the related notes. The financial statements have been prepared in the form prescribed under Section 10 of SI Number 179/2004 National Treatment Purchase Fund Board (Establishment) Order 2004, and in accordance with generally accepted accounting practice as modified by the Minister for Health in relation to accounting for superannuation costs.

Responsibilities of the members of the Board

The Board is responsible for the preparation of the financial statements, for ensuring that they give a true and fair view of the state of affairs of the National Treatment Purchase Fund Board and for ensuring the regularity of transactions.

Responsibilities of the Comptroller and Auditor General

My responsibility is to audit the financial statements and report on them in accordance with applicable law.

My audit is conducted by reference to the special considerations which attach to State bodies in relation to their management and operation.

My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) and in compliance with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements, sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of

- whether the accounting policies are appropriate to the Board's circumstances, and have been consistently applied and adequately disclosed
- the reasonableness of significant accounting estimates made in the preparation of the financial statements, and
- the overall presentation of the financial statements.

I also seek to obtain evidence about the regularity of financial transactions in the course of audit.

Opinion on the financial statements

In my opinion, the financial statements

- have been properly prepared under the accounting standards specified by the Minister for Health, and
- give a true and fair view in accordance with those standards of the National Treatment Purchase Fund Board's affairs as at 31 December 2016 and of its income and expenditure for 2016.

In my opinion, the accounting records of the National Treatment Purchase Fund Board were sufficient to permit the financial statements to be readily and properly audited. The financial statements are in agreement with the accounting records.

Emphasis of matter – Superannuation benefits

Without qualifying my opinion, I draw attention to Note 1 to the financial statements (accounting policy j) which discloses that, in compliance with the directions of the Minister for Health, the Board accounts for the costs of superannuation entitlements as they become payable, rather than recognising such costs in the year the entitlements are earned.

Matters on which I report by exception

I report by exception if I have not received all the information and explanations I required for my audit, or if I find

- any material instance where money has not been applied for the purposes intended or where the transactions did not conform to the authorities governing them, or
- the statement on internal financial control does not reflect the Board's compliance with the Code of Practice for the Governance of State Bodies, or
- there are other material matters relating to the manner in which public business has been conducted.

I have nothing to report in regard to those matters upon which reporting is by exception.

Patricia Sheehan

Patricia Sheehan

For and on behalf of the
Comptroller and Auditor General

25 January 2018

National Treatment Purchase Fund Board

Statement of Income and Expenditure and Retained Revenue Reserves For the year ended 31 December 2016

		2016	2015
	Notes	€	€
Income			
Oireachtas Grants	2	5,100,000	5,100,000
HSE Income	3	28,767,120	20,354,016
Superannuation contributions		74,330	90,382
Total Income		33,941,450	25,544,398
Less: Expenditure			
Patient Care Expenditure	4	30,387,932	21,345,689
Administration Expenses	5	3,899,689	3,271,331
Total Expenditure		34,287,621	24,617,020
(Deficit) / Surplus for the Year before Appropriations		(346,171)	927,378
Transfer from Capital Account	12	26,104	44,754
(Deficit) / Surplus for the Year after Appropriations		(320,067)	972,132
Balance Brought Forward at 1 January		1,154,253	182,121
Balance Carried Forward at 31 December		834,186	1,154,253

All income and expenditure for the year relates to continuing activities at the reporting date. The Statement of Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the year.

The Statement of Cash Flows and notes 1 to 15 form part of these financial statements

On Behalf of the National Treatment Purchase Fund Board:


John Horan
Chairperson
Date: 22/01/2018


Terry McWade
Board Member
Date: 22/01/2018

National Treatment Purchase Fund Board

Statement of Financial Position as at 31 December 2016

		2016	2015
	Notes	€	€
Fixed Assets	7	99,174	125,278
Current Assets			
Receivables and Prepayments	8	399,191	12,668,104
Cash at Bank and Cash in Hand	9	1,726,272	2,123,481
		<u>2,125,463</u>	<u>14,791,585</u>
Current Liabilities (amounts falling due within one year)			
Care Payables and Accruals	10	931,191	13,456,964
Non-Care Payables and Accruals	11	360,084	180,368
		<u>1,291,276</u>	<u>13,637,332</u>
Net Current Assets		<u>834,186</u>	<u>1,154,253</u>
Total Net Assets		<u>933,360</u>	<u>1,279,531</u>
Representing			
Income and Expenditure Account		834,186	1,154,253
Capital Account	12	99,174	125,278
		<u>933,360</u>	<u>1,279,531</u>

The Statement of Cash Flows and notes 1 to 15 form part of these financial statements

On Behalf of the National Treatment Purchase Fund Board:



John Horan
Chairperson
Date: 22/01/2018



Terry McWade
Board Member
Date: 22/01/2018

National Treatment Purchase Fund Board

Statement of Cash Flows

For the year ended 31 December 2016

		2016	2015
	Note	€	€
Net Cash Flow from Operating Activities			
(Deficit) / Surplus of Income over Expenditure		(346,171)	927,378
Depreciation and impairment of fixed assets	7	66,082	60,495
Decrease / (Increase) in receivables		12,268,913	(12,472,742)
(Decrease) / Increase in payables		(12,346,055)	11,961,698
Net Cash Inflow from Operating Activities		(357,231)	476,829
Cash Flows from Investing Activities			
Payments to acquire property, plant and equipment	7	(39,978)	(15,742)
Net Cash Flows from Investing Activities		(39,978)	(15,742)
Net (Decrease) / Increase in Cash and Cash Equivalents		(397,209)	461,087
Cash and Cash Equivalents at 1 January		2,123,481	1,662,394
Cash and Cash Equivalents at 31 December		1,726,272	2,123,481

National Treatment Purchase Fund Board

Notes to the financial statements For the year ended 31 December 2016

1. Accounting Policies

The basis of accounting and significant accounting policies adopted by the National Treatment Purchase Fund Board (NTPF Board) are set out below. They have all been applied consistently throughout the year and for the preceding year.

a) General Information

The NTPF Board was set up under the National Treatment Purchase Fund Board (Establishment) Order 2004 with a head office at Ashford House, Tara Street, Dublin 2.

The NTPF Board's primary objectives are as follows:

- (i) To make arrangements with persons, whether resident in the State or elsewhere, for the provision of hospital treatment to such classes of persons as may be determined by the Minister from time to time.
- (ii) To collect, collate and validate information in relation to persons waiting for hospital treatment and to put in place information systems and procedures for that purpose.
- (iii) To furnish whenever so required by the Minister or on its own initiative, advice to the Minister on issues relating to its functions.
- (iv) To negotiate with proprietors of registered nursing homes to reach agreement in relation to the maximum prices(s) that will be charged for the provision of long-term residential care services to Nursing Homes Support Scheme Residents and provide the HSE with the details of all approved Nursing Homes agreements.
- (v) To develop and implement schemes to support and facilitate the gradual reduction in maximum outpatient first appointment waiting times.
- (vi) To support measures to facilitate improved patient experience time and performance in hospital emergency departments through targeted programmes of support.

In February 2016, the Department of Health clarified the short and medium term function of the NTPF. In the short term, the Department considers it appropriate for NTPF to continue its current role for the purpose of;

- supporting the HSE in the delivery of improved waiting times for scheduled care, particularly in relation to the management of inpatient day case and outpatient waiting lists
- working with the HSE to assist hospitals in the development of local demand and capacity planning tools and mechanisms

National Treatment Purchase Fund Board

Notes to the financial statements

For the year ended 31 December 2016

- working with the HSE to develop hospital diagnostic waiting lists
- developing technical guidance materials for hospitals to ensure the highest standards of data analysis and quality practice

In the medium term, the Department will work with NTPF to explore the possibility of extending the organisations remit into the area of community and primary care waiting lists. The long term future role of the NTPF Board is being considered in the context of the wider Health Reform Programme.

The NTPF Board is a Public Benefit Entity (PBE)

b) Statement of Compliance

The financial statements of the NTPF Board for the year ended 31 December 2016 have been prepared in accordance with FRS 102, the financial reporting standard applicable in the UK and Ireland, issued by the Financial Reporting Council (FRC).

The NTPF Board has adopted FRS 102 in accordance with accounting standards except that pensions are accounted for on a pay-as-you-go basis. The provisions of FRS 102 Section 28 Employee Benefits are not applied and the liability for future pension benefits accrued in the year has not been recognised in the financial statements.

c) Basis of Preparation

The financial statements have been prepared under the historical cost convention, except for certain assets and liabilities that are measured at fair value as explained in the accounting policies below.

The financial statements are in the form approved by the Minister for Health with the concurrence of the Minister for Finance under the National Treatment Purchase Fund Board (Establishment) Order 2004.

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to NTPF Board's financial statements.

d) Revenue

Oireachtas Grants

Revenue is generally recognised on an accruals basis. However, Oireachtas Grants are provided to meet liabilities maturing during the year as opposed to expenses incurred during the year and are accounted for on a cash receipts basis.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

Health Service Executive Income

Income from the Health Service Executive is recognised in the year in which the medical care is provided.

Other Revenue

Other revenue is recognised on a cash receipts basis.

e) Patient care expenditure

Care expenditure is recognised in the year in which the medical care is provided.

f) Property, Plant and Equipment

Property, plant and equipment are stated at cost less accumulated depreciation, adjusted for any provision for impairment. Depreciation is provided on all property, plant and equipment on a straight line basis at rates which are estimated to reduce the assets to residual values by the end of their expected useful lives as follows:

Computer Software and Equipment	20% per annum
Office Equipment	20% per annum
Furniture and Fittings	10% per annum

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of an age and in the condition expected at the end of its useful life.

Expenditure incurred on the development of computer systems, which is substantial in amount, and is considered to have an economic benefit to the Board lasting more than one year into the future, is capitalised and depreciated over the period in which the economic benefits are expected to arise. This period is subject to a maximum of 5 years. In the event of uncertainty regarding its future economic benefit an impairment loss is recognised in the Statement of Income and Expenditure and Retained Revenue Reserves in the year.

g) Inventory

As the Board does not carry any material inventory all unused sundry consumable items (e.g. stationery, printed material etc.) are charged in full to the Statement of Income and Expenditure and Retained Revenue Reserves in the period in which they were first acquired.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

h) Receivables

Receivables are recognised at fair value, less provision for doubtful debts. The provision for doubtful debts is a specific provision, and is established when there is objective evidence that the NTPF Board will not be able to collect all amounts owed to it. All movements in the provision for doubtful debts are recognised in the Statement of Income and Expenditure and Retained Revenue Reserves.

i) Operating Leases

Rental expenditure under operating leases is recognised in the Statement of Income and Expenditure and Retained Revenue Reserves over the life of the lease. Expenditure is recognised on a straight line basis over the lease period.

j) Employee Benefits

Short-term Benefits

Short term benefits such as holiday pay are recognised as an expense in the year, and benefits that are accrued at year-end are included in the Payables figure in the Statement of Financial Position.

Retirement Benefits

Pension entitlements of employees directly employed by the Board are provided for through a defined benefit scheme currently being finalised with the Departments of Health and Public Expenditure & Reform. By direction of the Minister of Health, no provision is made in the financial statements in respect of future pension benefits. Funding is provided when pension payments are made.

Pension contributions deducted from employees' salaries are recognised as income in the Statement of Income and Expenditure and Retained Revenue Reserves. Pension payments are charged to the Statement of Income and Expenditure and Retained Revenue Reserves when paid.

NTPF also administer the Single Public Service Pension Scheme ("Single Scheme") which is a defined benefit scheme for pensionable public servants appointed on or after 1 January 2013. Single scheme members' contributions and employer contributions are paid over to the Department of Public Expenditure and Reform.

Pension benefits of staff seconded to the NTPF Board remain the responsibility of their parent bodies. The employer cost of providing these benefits is charged to the Statement of Income and Expenditure and Retained Revenue Reserves and is remitted to the parent bodies together with the relevant employee contributions.

k) Capital account

The capital account represents the unamortised value of income applied to capital expenditure. Releases are made from this reserve to the Income and Expenditure and Retained Revenue Reserves in line with the depreciation and write-down of the assets.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

l) Foreign Transactions

Foreign transactions during the period have been translated at the rate of exchange ruling at the date of the transaction.

m) Critical Accounting Judgements and Estimates

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. The nature of estimation means that actual outcomes could differ from those estimates. However, there were no judgements required that had a significant effect on amounts recognised in the financial statements for 2016.

Depreciation and Residual Values

The NTPF Board has reviewed the asset lives and associated residual values of all fixed asset classes, and in particular, the useful economic life and residual values of fixtures and fittings, and have concluded that asset lives and residual values are appropriate.

2 Oireachtas Grants

The Oireachtas Grants voted to National Treatment Purchase Fund Board from Vote 38 Health as shown in the financial statements consist of;

		2016	2015
		€	€
Grants for current expenditure	Sub-head E3	5,100,000	5,100,000

		2016	2015
		€	€
3 HSE Income			
NTPF/HSE Outsourcing initiative		28,767,120	20,354,016

During 2015 and 2016 NTPF provided administrative support to a special HSE initiative whereby longest waiting public patients were treated in private hospitals. This support concerned disbursing payments to the participating private hospitals. Funding in relation to this initiative originates in the Department of Health Vote Subheads I1 to I4 and is allocated to the HSE. Patient care expenditure of €28.77m incurred in 2016 (2015 €20.35m) was processed in this way by NTPF.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

4 (a) Patient Care Expenditure

In 2016 expenditure incurred by NTPF related to payments to private hospitals to provide inpatient and outpatient services to patients who had been on waiting lists for in excess of 18 months. The expenditure is broken down by payee and speciality as follows;

4 (b) Patient Care Expenditure by payee	2016	2015
	€	€
Private Hospitals	30,387,932	21,330,689
Voluntary Hospitals	-	15,000
	<u>30,387,932</u>	<u>21,345,689</u>

4 (c) Patient Care Expenditure by speciality	2016	2015
	€	€
Orthopaedics	12,958,057	5,509,381
ENT	4,286,291	3,794,944
General Surgery	3,533,586	2,689,430
Ophthalmology	2,338,225	992,493
Gynaecology	1,416,340	430,835
Non-cosmetic Plastic Surgery	1,402,816	977,058
Vascular Surgery	1,219,941	561,278
Urology	1,203,697	2,473,238
Neurosurgery	652,283	1,378,357
Cardiac Surgery/ Cardiology	614,518	1,537,431
Radiology	408,064	770,633
Dental and Oral Surgery	208,575	110,575
Surgical Dermatology	78,846	45,944
Rheumatology	35,832	42,281
Pain Management	26,741	757
Neurology	4,119	31,055
Total	<u>30,387,932</u>	<u>21,345,689</u>

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

		2016	2015
		€	€
5 Administration Expenses			
Payroll	Note 6	2,061,662	2,040,896
Office rent		603,805	442,897
Computer expenses		295,070	306,259
Office expenses		154,172	151,048
Transport and Travel		66,584	68,258
Professional services		414,941	61,624
Depreciation		66,082	60,495
Legal fees		38,303	53,930
Training and Recruitment		56,780	25,221
Premises cleaning and maintenance		23,261	20,553
Insurance		11,059	10,158
Board expenses	Note 6 (d)	12,749	10,068
Advertising and Promotion		78,062	8,795
Audit fees		14,000	8,500
Miscellaneous costs		2,554	2,089
Bank charges		604	540
		<u>3,899,689</u>	<u>3,271,331</u>

The costs of administering NTPF's role under the Nursing Homes Support Scheme Act are included in salaries and overheads. These costs amount to €375,566 (2015 €299,173).

6 Remuneration and Pay Costs

6(a) Salaries and Pensions		2016	2015
		€	€
Staff Salaries :			
Management		315,230	259,195
Administration		1,676,246	1,711,515
Board Fees		70,186	70,186
Total Payroll Cost		<u>2,061,662</u>	<u>2,040,896</u>

Pension levy deductions of €83,212 (2015 €118,875) were made from staff salaries and remitted to the Department of Health.

National Treatment Purchase Fund Board

Notes to the financial statements (cont.)

For the year ended 31 December 2016

6(a) Salaries and Pensions (cont.)

Pending consideration of NTPF's role, 3 employees were on temporary secondment to other Health Agencies during 2016. Salary costs relating to these staff are being recouped from the Agencies in question. A further 11 employees, with a salary cost of €393,537 (2015 €436,764) were similarly assigned to other Health Agencies without salary recoupment to the Board. On the 31 December 2017 arrangements were put in place so that all secondees would either transfer on a permanent basis to other agencies or alternatively return to employment with the NTPF.

	2016	2015
Average Number of Employees during the year	46	45
Of which were seconded	-14	-18
6(b) Chief Executive's Salary	€	€
	-	-

The Chief Executive Officer (CEO) was appointed on an acting basis with effect from 28 May 2014. The Acting CEO did not receive any remuneration from NTPF in respect of this role. In addition to the role and duties as Acting CEO with NTPF, the CEO also carried out the role of Assistant National Director in the Office of the Director General of the HSE and was paid in line with the HSE consolidated pay scales.

6(c) Employee benefits breakdown		Number of Employees	
		2016	2015
From	To		
€60,000	- €69,999	4	4
€70,000	- €79,999	2	2
€80,000	- €89,999	-	-
€90,000	- €99,999	-	-
€100,000	- €109,999	1	1
Total		7	7

National Treatment Purchase Fund Board

Notes to the financial statements (cont.)

For the year ended 31 December 2016

6 Remuneration and Pay Costs (cont.)

6(d) Board Members' Emoluments

Board Member	Board Fees	PRSI on Board Fees	Vouched Expenses	Total 2016	Total 2015
	€	€	€	€	€
John Horan (Chair)	11,970	0	1,324	13,294	12,902
Sheila Bailey	7,695	654	2,494	10,844	9,497
Patrick Gibbons	7,695	654	181	8,530	8,550
Terry McWade	7,695	654		8,349	8,349
James Melly	7,695		635	8,330	8,050
Jack Nagle	7,695	654	3,037	11,386	12,569
Brendan O'Donoghue	7,695	654		8,349	8,349
Anne-Marie Taylor	7,695	654		8,349	8,349
Bernadette Costello			5,078	5,078	3,212
Martin Barron (advisor)	424	2		426	426
Total	66,259	3,927	12,749	82,935	80,253

Board Member	Meetings attended		
	Board (9)	Audit & Risk Committee (6)	Strategy Committee (11)
John Horan (Chair)	9		
Sheila Bailey	7		8
Patrick Gibbons	9	6	
Terry McWade	9	6	
James Melly	9		11
Jack Nagle	8		10
Brendan O'Donoghue	9	6	8
Anne-Marie Taylor	8		10
Bernadette Costello	9	5	
Martin Barron (advisor)			

National Treatment Purchase Fund Board

Notes to the financial statements (cont.)

For the year ended 31 December 2016

7 Property, Plant & Equipment

	Computer Equipment and Software	Office Equipment	Furniture, Fixtures and Fittings	Total
Depreciation Rate	20%	20%	10%	
	€	€	€	€
Cost				
At 1 January 2016	4,746,525	157,408	386,434	5,290,367
Additions	38,754	1,224	-	39,978
Disposals	-	-	-	-
At 31 December 2016	4,785,279	158,632	386,434	5,330,345
Depreciation				
At 1 January 2016	(4,632,238)	(150,701)	(382,151)	(5,165,089)
Charge for the Year	(60,818)	(2,921)	(2,343)	(66,082)
Disposals	-	-	-	-
At 31 December 2016	(4,693,056)	(153,621)	(384,494)	(5,231,171)
Net Book Value				
At 1 January 2016	114,287	6,707	4,284	125,278
Net movement for the year	(22,064)	(1,697)	(2,343)	(26,104)
At 31 December 2016	92,223	5,010	1,941	99,174

	2016 €	2015 €
8 Receivables and prepayments		
Receivables - Health Services Executive	173,388	12,650,614
Sundry Prepayments	220,272	11,215
Other Sundry Receivables	5,531	6,275
	399,191	12,668,104
9 Cash at Bank and in Hand		
Bank Current Account	1,725,972	2,123,181
Petty Cash	300	300
	1,726,272	2,123,481

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

	2016	2015
	€	€
10 Care Payables and Accruals		
Care payables	325	142,047
Care accruals	930,866	13,314,917
	<u>931,191</u>	<u>13,456,964</u>
	2016	2015
	€	€
11 Non-Care Payables and Accruals		
Professional Services Withholding Tax	140,626	35,431
PAYE / PRSI and Government Levies	57,375	64,430
Other non care payables and accruals	162,083	80,507
	<u>360,084</u>	<u>180,368</u>
	2016	2015
	€	€
12 Capital Account		
Balance at 1 January	125,278	170,032
Funds allocated to acquire fixed assets	39,978	15,742
Amortisation in line with asset depreciation	(66,082)	(60,495)
Balance at 31 December	<u>99,174</u>	<u>125,278</u>

13 Operating Leases

The National Treatment Purchase Fund occupies premises at Ashford House, Tara Street, Dublin 2 under a lease agreement commencing 1 January 2016 and expiring on 31 December 2020.

	2016	2015
	€	€
Operating lease rentals (charged to Income and Expenditure and Retained Reserves)		
Land and Buildings	603,805	442,897

National Treatment Purchase Fund Board

Notes to the financial statements (cont.) For the year ended 31 December 2016

13 Operating Leases (cont.)	2016	2015
	€	€
The Board has the following commitments under operating leases which expire		
Within 1 year	603,805	442,897
Within 2 to 5 years	2,415,218	-
Operating lease payments recognised as an expense were €603,805 (2015 €442,897)		

14 Related Party Disclosures

Key personnel of the NTPF Board consist of members of the Board, the CEO and Senior Managers. Total compensation paid to key personnel, including Board member's fees and expenses, amounted to €385,416 (2015 €339,449). For a breakdown of the remuneration and benefits paid to key personnel see Note 6.

The NTPF Board adopts procedures in accordance with the guidelines issued by the Department of Public Expenditure and Reform covering the personal interests of Board members. In the normal course of business the NTPF Board may enter into contractual arrangements with entities in which the NTPF Board members are employed or are otherwise interested.

During the year the NTPF Board had no dealings with bodies connected to any of the Board members.

15 Approval of the financial statements

The financial statements were approved by the National Treatment Purchase Fund Board on 22 January 2018